Nanotechnology Now - Press Release: A nanoparticle does double duty, imaging and treating atherosclerosis

Home > Press > A nanoparticle does double duty, imaging and treating atherosclerosis

Abstract:
Title

Self-therapeutic HDL mimicking nanoparticles for detection of atherosclerotic plaques

Abstract

Plaque build up inside arteries due to excessive cholesterol deposition is the hallmark of atherosclerotic heart disease [1]. Early detection of vulnerable atherosclerotic plaques could prove to be highly useful for diagnosis and therapy of the disease. Magnetic resonance imaging (MRI) is one such techniques that can be employed for efficient detection of plaques [2]. With these objectives in mind, we have designed iron oxide loaded high density lipoprotein (HDL) mimicking nanoparticles [3] that not only enables MR imaging of atherosclerotic plaques but also are capable of removing cholesterol and triglyceride from the body. These nanoparticles were impregnated with suitable surface functionalities so that they can target macrophages selectively and thus can enhance MRI contrast. The technology described here uses biocompatible polymers and lipids for the construction of a HDL mimicking biodegradable nanoparticle and it could be a potent theranostic tool for coronary heart diseases.

1. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993. 362(6423): p. 801-809.

2. Fleg, J.L., et al., Detection of High-Risk Atherosclerotic Plaque: Report of the NHLBI Working Group on Current Status and Future Directions. JACC. Cardiovascular imaging, 2012. 5(9): p. 941-955.

3. Marrache, S. and S. Dhar, Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proceedings of the National Academy of Sciences, 2013. 110(23): p. 9445-9450

A nanoparticle does double duty, imaging and treating atherosclerosis

San Diego, CA | Posted on March 13th, 2016

Atherosclerosis, a disease in which plaque builds up inside arteries, is a prolific and invisible killer, but it may soon lose its ability to hide in the body and wreak havoc. Scientists have now developed a nanoparticle that functionally mimics nature's own high-density lipoprotein (HDL). The nanoparticle can simultaneously light up and treat atherosclerotic plaques that clog arteries. Therapy with this approach could someday help prevent deadly heart attacks and strokes.

The researchers present their work today at the 251st National Meeting & Exposition of the American Chemical Society (ACS). ACS, the world's largest scientific society, is holding the meeting here through Thursday. It features more than 12,500 presentations on a wide range of science topics.

"Other researchers have shown that if you isolate HDL components from donated blood, reconstitute them and inject them into animals, there seems to be a therapeutic effect," says Shanta Dhar, Ph.D. "However, with donors' blood, there is the chance of immunological rejection. This technology also suffers scale-up challenges. Our motivation was to avoid immunogenic factors by making a synthetic nanoparticle which can functionally mimic HDL. At the same time, we wanted a way to locate the synthetic particles."

Current detection strategies often fail to identify dangerous plaques, which can clog arteries over time or break off from arterial walls and block blood flow, causing a heart attack or stroke. Magnetic resonance imaging (MRI) offers a potential approach for plaque visualization, but requires the use of a contrast agent to show the atherosclerotic plaques clearly. But the potential for harmful immune reactions still exists with the use of donor-derived HDL.

Beyond imaging, there is a therapeutic aspect of using HDL. HDL is widely known as "good" cholesterol because of its ability to pull low-density lipoprotein, or "bad" cholesterol, out of plaques. This process shrinks the plaques, making them less likely to clog arteries or break apart.

To simultaneously identify and treat atherosclerosis without triggering an immune response, Dhar and Bhabatosh Banik, Ph.D., a postdoctoral fellow in her lab, created an MRI-active HDL mimic. The researchers, who are at the University of Georgia, Athens, had previously built synthetic HDL particles lacking a contrast agent. These particles lowered levels of total cholesterol and triglycerides in mice.

"The key challenge, then, was designing the contrast agent," Banik says. "It took time to figure out the optimal lipophilicity and solubility." The contrast agent, iron oxide, needs to be encapsulated in the synthetic lipoparticle's hydrophobic core to provide the brightest possible signal. Eventually, the researchers hit on the right chemical combination -- iron oxide with a fatty surface coating -- for optimal particle encapsulation. They successfully visualized the contrast agent using MRI in cell studies.

The researchers are applying their synthetic nanoparticle to distinguish between unstable plaques and stationary ones. To do this, Dhar targeted the new MRI-active HDL mimics to macrophages, which are white blood cells that, along with lipids and cholesterol, make up atherosclerotic plaques.

The researchers targeted macrophages by decorating the nanoparticles' surfaces with a molecule that selectively binds to macrophages. The team observed that the nanoparticles were engulfed by these white blood cells. "Then, when the macrophages ruptured, which is a sign of an unstable plaque, the cells spit out the nanoparticles, causing the MRI signal to change in a detectable fashion," Banik says.

Dhar says her lab is now using MRI to study how well the particles light up and treat plaques in animals, and she hopes to begin clinical trials within two years.

Dhar acknowledges funding from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the American Heart Association.

####

About American Chemical Society
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 158,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

For more information, please click here

Contacts:
619-525-6215 (San Diego Press Center, March 13-16)

Michael Bernstein
202-872-6042 (D.C. Office)
301-275-3221 (Cell)

Katie Cottingham, Ph.D.
301-775-8455 (Cell)

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: